The role of SARS‐CoV‐2 target ACE2 in cardiovascular diseases. Issue 3 (14th January 2021)

• Record Type: Journal Article
• Authors: Zhu, Hanzhao; Zhang, Liyun; Ma, Yubo; Zhai, Mengen; Xia, Lin; Liu, Jincheng; Yu, Shiqiang; Duan, Weixun
• Is Part Of: Journal of cellular and molecular medicine. Volume 25:Issue 3(2021)
• Page Start: 1342
• Page End: 1349
• Publication Date: 2021-01-14
• Subjects: ACE2 -- cardiovascular diseases -- RAS -- SARS‐CoV‐2; Cytology; Medicine; Molecular Biology; Cytologie -- Périodiques; Médecine -- Périodiques; Biologie moléculaire -- Périodiques; Cytology -- Periodicals; Medicine -- Periodicals; Molecular biology -- Periodicals; 611.01805
• DOI: 10.1111/jcmm.16239
• Languages: English
• ISSNs: 1582-1838

Abstract

Abstract: SARS‐CoV‐2, the virus responsible for the global coronavirus disease (COVID‐19) pandemic, attacks multiple organs of the human body by binding to angiotensin‐converting enzyme 2 (ACE2) to enter cells. More than 20 million people have already been infected by the virus. ACE2 is not only a functional receptor of COVID‐19 but also an important endogenous antagonist of the renin‐angiotensin system (RAS). A large number of studies have shown that ACE2 can reverse myocardial injury in various cardiovascular diseases (CVDs) as well as is exert anti‐inflammatory, antioxidant, anti‐apoptotic and anticardiomyocyte fibrosis effects by regulating transforming growth factor beta, mitogen‐activated protein kinases, calcium ions in cells and other major pathways. The ACE2/angiotensin‐(1‐7)/Mas receptor axis plays a decisive role in the cardiovascular system to combat the negative effects of the ACE/angiotensin II/angiotensin II type 1 receptor axis. However, the underlying mechanism of ACE2 in cardiac protection remains unclear. Some approaches for enhancing ACE2 expression in CVDs have been suggested, which may provide targets for the development of novel clinical therapies. In this review, we aimed to identify and summarize the role of ACE2 in CVDs.